



For the promotion
and recognition
of excellence
in orphan disease
treatment research

The Review Committee

Chairman:

Robert J. Desnick Ph.D, M.D.
Dean for Genetics and Genomic
Medicine, Professor and Chair
Emeritus Department of Genetic
& Genomic Sciences, Mount Sinai
School of Medicine, New York, USA

Andrea Giustina M.D.
Full Professor and Chair
Institute of Endocrinology
and Metabolic Sciences (IEMS)
San Raffaele Vita-Salute University,
IRCCS San Raffaele Hospital,
Milan, Italy

Shlomo Melmed M.D., ChB.
Dean of the Medical Faculty
and Professor of Medicine,
Cedars Sinai Medical Centre,
Los Angeles, USA

For more information:
www.prize.recordati.it
www.recordati.com/it/

Recordati S.p.A
Via M. Civitali, 1
20148 Milan, Italy
Ph +39 02 48787.1
Fax +39 02 40 073 747
www.recordati.com

THE TENTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI COMES TO END

In 2022 The Prize was dedicated to the promotion and recognition of excellence in research on pituitary disorders

Dr Sabrina Chiloiro's project aiming to investigate the role of the immune microenvironment in GH secreting pituitary tumors was awarded with a €100,000 research grant

Milan, 23rd May 2022

During the 24th European Congress of Endocrinology, the Tenth edition of the International Prize for Scientific Research Arrigo Recordati came to its conclusion with a €100,000 research grant awarded to Sabrina Chiloiro, MD and PhD, clinical and translational endocrine researcher at the Pituitary Unit of the Endocrinology Department at the Catholic University of the Sacred Heart, in Rome.

2022 International Prize for Scientific Research Arrigo Recordati

The Prize was established in 2000 by Recordati Group in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati to perpetuate his legacy and to inspire biomedical discoveries benefiting people worldwide. Arrigo Recordati strongly believed in the power of the research to drive the development of the pharmaceutical industry and provide products beneficial to public health and individual wellbeing.

This year marks the Tenth edition of the Prize which, in line with Recordati's ever-growing commitment in rare diseases and endocrinology through its division Recordati Rare Diseases, was dedicated to the promotion and recognition of excellence in research on pituitary disorders.

This edition has seen applications coming through by thirty junior researchers of different nationalities, which have been assessed by the 2022 Review Committee - an independent panel of internationally recognized experts who have provided leadership throughout their long careers in the field of rare diseases, including Chairman Robert J. Desnick Ph.D, M.D., Andrea Giustina M.D. and Shlomo Melmed M.D., ChB.

During the Award ceremony, the Committee, in the presence of Andrea Recordati, was delighted to announce that **Dr Sabrina Chiloiro's project was awarded with the € 100,000 Arrigo Recordati Prize.**

*"We are increasingly committed to meeting the needs of patients suffering from rare diseases by sustaining the research of new therapies in this area," said **Andrea Recordati, Chairman of Recordati Group** announcing the winner. "On behalf of Recordati Group, Robert Desnick, Andrea Giustina, Shlomo Melmed, and myself, it is an honour and a privilege to award the outstanding Dr Sabrina Chiloiro's research project that will offer the opportunity to identify new biomarkers for the development of a targeted and personalized therapy of acromegaly".*

*"Recordati Rare Diseases is committed to improving the lives of patients with serious and underserved conditions and the Arrigo Recordati Award is a reflection of our obligation. On behalf of the company, I would like to congratulate Dr Chiloiro and thank all the patients, families, carers, and those who have contributed to finding innovative solutions to rare diseases", said **Scott Pescatore, Executive Vice President at Recordati Rare Diseases.***



**For the promotion
and recognition
of excellence
in orphan disease
treatment research**

The Review Committee

Chairman:

Robert J. Desnick Ph.D, M.D.
Dean for Genetics and Genomic
Medicine, Professor and Chair
Emeritus Department of Genetic
& Genomic Sciences, Mount Sinai
School of Medicine, New York, USA

Andrea Giustina M.D.

Full Professor and Chair
Institute of Endocrinology
and Metabolic Sciences (IEMS)
San Raffaele Vita-Salute University,
IRCCS San Raffaele Hospital,
Milan, Italy

Shlomo Melmed M.D., ChB.

Dean of the Medical Faculty
and Professor of Medicine,
Cedars Sinai Medical Centre,
Los Angeles, USA

For more information:

www.prize.recordati.it
www.recordati.com/it/

Recordati S.p.A

Via M. Civitali, 1
20148 Milan, Italy
Ph +39 02 48787.1
Fax +39 02 40 073 747
www.recordati.com

Sabrina Chiloiro, after expressing huge satisfaction for receiving the prestigious Award, gave a rapid lecture summarizing her research project.

The ACRO-TIME study

The research project “The role of the tumor immune microenvironment (TIME) in the prognosis and in the personalized target therapy of acromegaly: the ACRO-TIME study” has the aim to investigate the role of the immune microenvironment in GH secreting pituitary tumors. The TIME includes immune cells, endothelial cells, extracellular matrix and soluble factors. Until now, few studies have investigated the TIME in GH-omas. “In-vitro” studies showed that GH and IGF-I modulate the immune response and that somatostatin contributes to control the proliferation and the activity of inflammatory cells. The tumor immune microenvironment (TIME) may explain the great heterogeneity in biological behavior of GH-secreting pituitary adenoma (GH-omas). As such, the infiltration of immune cells and the other components of the TIME (such as antibodies, tumor blood vessels, cytokines and chemokines, macromolecules of the extracellular matrix and their receptors) will be carefully characterized in GH-omas to understand their real role. The ACRO-TIME study will offer the opportunity to identify new biomarkers for the development of a targeted and personalized therapy, rationalizing the use of ICIs and inhibitors of angiogenesis in aggressive and multi-treatments resistant GH-omas.

2022 Award Winner: Dr Sabrina Chiloiro

Sabrina Chiloiro, MD and PhD is a clinical and translational endocrine researcher at the Pituitary Unit of the Endocrinology Department at the Catholic University of the Sacred Heart, in Rome, where she graduated in Medicine and Surgery with full honors in 2011, discussing a degree thesis on the prognostic role of the proliferative index in pituitary adenomas, that was awarded at the “6th Edition of Italian Hypothalamus Pituitary Meeting” in 2012.

In 2012 and 2013 she followed a post-graduated research fellow on “New technology in molecular medicine” at the Padua University. She trained in Endocrinology and started her research projects, at the Pituitary Unit of the Catholic University of the Sacred Heart from 2013 to 2018, mentoring by Prof. Laura De Marinis. During the whole of 2019 she was Research Fellow at the Pituitary Unit of the Endocrinology Department. She received the PhD degree in 2021 conducting a research project on primary and immuno-therapy induced hypophysitis. Her research covers a broad range of translational and clinical topics on pituitary disease including secreting and not secreting pituitary neoplasia, acromegaly, prolactinoma, hypophysitis, hypopituitarism and bone fragility.

She is active in international collaborative studies and phase I/II/III clinical trials on acromegaly, hypopituitarism, and neuroendocrine tumors. Dr Chiloiro has authored on peer-reviewed original articles, reviews, editorials, commentaries, book chapters and abstracts, and has been a speaker at national and international congresses. She is highly involved in teaching medical students, residents, and physician assistant students.

Dr Sabrina Chiloiro was honored by the European Society of Endocrinology with the Young Investigator Award for the research “Effect of Pegvisomant and somatostatin receptor ligands on the risk of vertebral fractures in patients with acromegaly” in 2017.

Acromegaly

Acromegaly is a rare hormonal disorder characterized by an over-production of Growth Hormone (GH) by the pituitary gland. The pituitary gland is an endocrine



**For the promotion
and recognition
of excellence
in orphan disease
treatment research**

The Review Committee

Chairman:

Robert J. Desnick Ph.D, M.D.
Dean for Genetics and Genomic
Medicine, Professor and Chair
Emeritus Department of Genetic
& Genomic Sciences, Mount Sinai
School of Medicine, New York, USA

Andrea Giustina M.D.

Full Professor and Chair
Institute of Endocrinology
and Metabolic Sciences (IEMS)
San Raffaele Vita-Salute University,
IRCCS San Raffaele Hospital,
Milan, Italy

Shlomo Melmed M.D., ChB.

Dean of the Medical Faculty
and Professor of Medicine,
Cedars Sinai Medical Centre,
Los Angeles, USA

gland located at the base of the brain involved in the synthesis of several hormones including GH. The first symptom of this disorder is the abnormal growth of the hands and feet and more generally an increase of the bones size. Even though Acromegaly can develop at any age, it usually affects middle-aged women and men. Because Acromegaly is uncommon and physical changes occur very slowly, the condition sometimes takes from 3 to 6 years to be diagnosed and can lead to severe complications such as severe damage to the joints and problems affecting the cardiovascular and respiratory systems. In Europe, Acromegaly affects approximately 1.2 in 10,000 people.

Recordati Rare Diseases: focused on the few

Over the last fifteen years Recordati has made the rare diseases field a health priority and has increased its commitment worldwide through Recordati Rare Diseases, a group of companies operating globally and dedicated entirely to serve patients suffering from these diseases. The Group's specialty rare disease products are marketed directly by Recordati Rare Diseases in Europe, the Middle East, the U.S.A., Canada, Russia, Japan, and Australia, in some Latin American countries, and through selected partners in other parts of the world.

Highly trained specialists and a scientific support team are available to collaborate with doctors, healthcare professionals, patient groups and families, to help improve the quality of life for people with rare diseases.

Thanks to a unique production, packaging and distribution system developed for products, the Group's dedicated specialists are able to support patients in their home countries.

Recordati Rare Diseases is committed to supporting families affected by rare diseases through the research and development of new therapies and the distribution of specific scientific knowledge throughout the medical community.

***Recordati**, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing, and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan, and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2021 was € 1,580.1 million, operating income was € 490.2 million and net income was € 386.0 million.*

For more information:

**Investor Relations & Corporate
Communications**

Federica De Medici
(39) 02 48787146
e-mail: investorelations@recordati.it

Press Office

Brunswick: Barbara Scalchi / Andrea
Mormandi
(39) 02 9288 6200
e-mail: recordati@brunswickgroup.com

For more information:
www.prize.recordati.it
www.recordati.com/it/

Recordati S.p.A
Via M. Civitali, 1
20148 Milan, Italy
Ph +39 02 48787.1
Fax +39 02 40 073 747
www.recordati.com